Background illustration for clinical trials search

Paid Clinical Trials Hershey

Discover 525 paid clinical trials in Hershey, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for
Advanced Malignant Solid Neoplasm,
Location: Mechanicsburg PA, Hazleton PA, Allentown PA, Paoli PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

for
Malignant Female Reproductive System Neoplasm,
Location: Mechanicsburg PA, Baltimore MD, Willow Grove PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06126276

Phase2, Recruiting

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

for
Coronary Arterial Disease (CAD),
Location: Mechanicsburg PA, York PA, Falls Church VA, Brooklyn NY,
Sponsor: Boston Scientific Corporation

Sex: All

Age: 18+

Code: NCT06959524

Recruiting

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

for
Chronic Diabetic Foot Ulcers
Location: York PA, New York NY, Ford City PA, Kittanning PA,
Sponsor: SerenaGroup, Inc.

Sex: All

Age: 18+

Code: NCT04457752

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

for
Metastatic Prostate Cancer
Location: Lancaster PA, Baltimore MD, Silver Spring MD,
Sponsor: ORIC Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT05413421

Phase1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Location: Lancaster PA, Bala-Cynwyd PA, Hanover MD,
Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06545955

Phase3, Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

for
Non-Muscle Invasive Bladder Cancer
Location: Lancaster PA, Bala-Cynwyd PA, New Brunswick NJ,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06319820

Phase3, Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Location: Lancaster PA, Bala-Cynwyd PA, Philadelphia PA,
Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06510374

Phase3, Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

for
Non-Muscle Invasive Bladder Neoplasms
Location: Lancaster PA, Bala-Cynwyd PA, Voorhees Township NJ,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06919965

Phase3, Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

for
Metastatic Castration Sensitive Prostate Cancer (mCSPC),
Location: Lancaster PA, Bala-Cynwyd PA, Basking Ridge NJ,
Sponsor: Pfizer

Sex: Male

Age: 18+

Code: NCT07028853

Phase3, Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for
Metastatic Castration-resistant Prostatic Neoplasms
Location: Lancaster PA, Baltimore MD, Bala-Cynwyd PA,
Sponsor: Janssen Research & Development, LLC

Sex: Male

Age: 18+

Code: NCT07164443

Phase3, Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

for
Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations,
Location: Lancaster PA, Baltimore MD, Bala-Cynwyd PA,
Sponsor: Tyra Biosciences, Inc

Sex: All

Age: 18+

Code: NCT06995677

Phase2, Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: Lancaster PA, Towson MD, Bala-Cynwyd PA, North Hills NY,
Sponsor: Dendreon

Sex: Male

Age: 18+

Code: NCT06134232

Phase2, Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

for
Non-small Cell Lung Cancer
Location: Lancaster PA, New York NY, Syracuse NY, Rochester NY,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06561386

Phase3, Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

for
Urinary Bladder Neoplasms, Neoplasm Metastasis,
Location: Lancaster PA, Baltimore MD, Philadelphia PA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT05614739

Phase1, Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

for
Non-small Cell Lung Cancer
Location: Lancaster PA, Morristown NJ, Stamford CT, Albany NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06345729

Phase3, Recruiting

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

for
Colorectal Cancer
Location: Lancaster PA, Philadelphia PA, Fairfax VA,
Sponsor: Criterium, Inc.

Sex: All

Age: 18+

Code: NCT06992258

Phase2, Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for
Non-small Cell Lung Cancer
Location: Lancaster PA, Hackensack NJ, Fredericksburg VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07190248

Phase3, Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

for
Ovarian Cancer
Location: Lancaster PA, Towson MD, Bethlehem PA, Paramus NJ,
Sponsor: Daiichi Sankyo

Sex: Female

Age: 18+

Code: NCT06819007

Phase3, Recruiting

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

for
Amblyopia
Location: Lancaster PA, Baltimore MD, Philadelphia PA,
Sponsor: Jaeb Center for Health Research

Sex: All

Age: 4 - 7

Code: NCT06380517

Phase3, Recruiting